Letrozole
Femara — nonsteroidal aromatase inhibitor
Letrozole (Femara — nonsteroidal aromatase inhibitor) is a hormonal & sexual research compound. A nonsteroidal competitive inhibitor of aromatase (CYP19A1), the enzyme that converts androstenedione to estrone and testosterone to estradiol. Reversible, unlike exemestane, which is a steroidal substrate analog that inactivates the enzyme permanently. The label reports suppression of plasma estradiol, estrone and estrone sulfate by 75-95% from baseline, with no significant effect on adrenal corticosteroid, aldosterone or thyroid hormone synthesis. Cleared by CYP3A4 and CYP2A6 to a carbinol metabolite, then glucuronidated and excreted renally.
Letrozole quick facts
| Route | Oral |
| Frequency | 1x Daily · Per prescription |
| Half-life | ~2 days (terminal); steady state takes 2-6 weeks |
| Forms | Oral |
| Evidence level | FDA-approved (adjuvant and advanced breast cancer, postmenopausal women). High-certainty Cochrane evidence for ovulation induction in PCOS. No trial in men. |
The strongest of the three aromatase inhibitors, and the head-to-head proves it rather than asserting it: in 79 patients crossed over from one drug to the other, letrozole took mean serum estrone to 0.2 pmol/L where exemestane left it at 1.8 — roughly nine times more residual estrone on the steroidal drug, in the same person. Two numbers explain most of the trouble people have with it. The label's suppression range is 75-95%, which is a twenty-point spread nobody can predict in advance; and the terminal half-life is about two days with steady state taking two to six weeks, so a reassuring blood test at day four is measuring an incomplete accumulation. Prescription-only, no buy route here. Its best evidence is a Cochrane review of 41 trials in 6,522 women for ovulation induction — an indication nobody buys it for — and there is no randomized trial of it in men at all.
How Letrozole works
A nonsteroidal competitive inhibitor of aromatase (CYP19A1), the enzyme that converts androstenedione to estrone and testosterone to estradiol. Reversible, unlike exemestane, which is a steroidal substrate analog that inactivates the enzyme permanently. The label reports suppression of plasma estradiol, estrone and estrone sulfate by 75-95% from baseline, with no significant effect on adrenal corticosteroid, aldosterone or thyroid hormone synthesis. Cleared by CYP3A4 and CYP2A6 to a carbinol metabolite, then glucuronidated and excreted renally.
Proposed benefits
Researched for libido, hormonal signaling and reproductive / sexual function.
Where to get Letrozole
Buy Letrozole at RUPharma →A prescription aromatase inhibitor, and the strongest of the three — it suppresses whole-body estrogen synthesis by more than 98%, where anastrozole reaches the high 90s and exemestane sits below both.
Over-suppressed estradiol is the failure mode, and it costs joints, lipids, libido and bone. Sensitive estradiol is the assay that can actually read the low end — a standard estradiol test cannot tell 'low' from 'far too low', which is the exact distinction that matters on this drug.
Order these through my Marek link →The evidence for Letrozole
Graded by what exists behind each claim.
✅ Clinically validated
- FDA-approved for adjuvant, extended adjuvant and first- and second-line treatment of postmenopausal women with hormone receptor-positive breast cancer, at 2.5 mg once daily. Every estrogen-suppression number attached to this drug was measured in that population.
- Its strongest evidence is in an indication nobody buys it for. A Cochrane review of 41 randomized trials in 6,522 women with anovulatory PCOS found higher live birth rates than the SERM standard for ovulation induction — OR 1.72, 95% CI 1.40 to 2.11, high-certainty evidence — with ovarian hyperstimulation at 0.5% in both arms and no difference in miscarriage or multiple pregnancy (Franik 2022).
- There is no randomized trial of letrozole in men. Not a small one — none. The off-label case for estrogen control on testosterone is an enzyme mechanism transferred across a population with different substrate concentrations and a different feedback loop.
📊 Correlative data
- The head-to-head this class went decades without. In 79 postmenopausal patients crossed over from one drug to the other with an ultrasensitive LC-MS/MS assay, letrozole 2.5 mg suppressed mean serum estrone to 0.2 pmol/L and estradiol to 0.4 pmol/L; exemestane 25 mg, in the same people, left estrone at 1.8 pmol/L (Bertelsen 2024). Roughly nine times more residual estrone on the steroidal drug.
- The label's own figure is a range rather than a point: suppression of plasma estradiol, estrone and estrone sulfate by 75% to 95% from baseline. Twenty points of between-person variability, unpredictable in advance.
🧪 Theoretical / extrapolated
- The pharmacokinetics are the reason people crash on this drug. Terminal half-life about 2 days, steady state in 2 to 6 weeks. A blood test at day four is measuring an incomplete accumulation, and a dose correction takes about 10 days to show its full effect.
- The costs are quantified and silent. Median lumbar spine bone mineral density fell 4.1% at 24 months against a 0.3% rise on the comparator; hypercholesterolemia was reported in 52.3% of letrozole patients against 28.6%. Arthralgia and arthritis in 25.4%, and the aromatase-inhibitor musculoskeletal syndrome affects up to half of women on this class (Hyder 2021).
- Cleared principally by CYP3A4, so a strong inducer under-doses it and a strong inhibitor over-doses it — and the 2-to-6-week accumulation window means neither is obvious for a fortnight.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Letrozole actually does
What it does, at the enzyme, with the substrate and the product named. Aromatase is CYP19A1, and its job is to convert androgens into estrogens: androstenedione becomes estrone, testosterone becomes estradiol. Femara label 2026 describes letrozole as “a nonsteroidal competitive inhibitor of the aromatase enzyme system” that “inhibits the conversion of androgens to estrogens”. Competitive and reversible — which is the whole structural difference from exemestane, a steroidal substrate analog that inactivates the enzyme permanently and is therefore described as an aromatase inactivator rather than an inhibitor.
The number that separates it from its two shelf-mates, and it was measured within-subject. Bertelsen 2024 is the head-to-head that this class went decades without: postmenopausal breast cancer patients randomized to letrozole 2.5 mg daily or exemestane 25 mg daily, then crossed over onto the other drug, with serum estrone, estradiol and both drug levels quantified by an ultrasensitive LC-MS/MS method. Complete sample sets from 79 patients. Baseline mean estrone was 174 pmol/L and estradiol 46.4 pmol/L. On letrozole those fell to 0.2 pmol/L and 0.4 pmol/L; on exemestane, in the same people, to 1.8 pmol/L and 0.6 pmol/L. Roughly nine times more residual estrone on the steroidal drug, in the same patient, on the same assay.
The label's own range says the same thing less precisely, and the width of it is the warning. Femara label 2026: daily dosing suppresses plasma estradiol, estrone and estrone sulfate by 75% to 95% from baseline. A twenty-point spread is not a rounding convention — it is the actual between-person variability of this drug's effect, and nobody can tell in advance which end of it they are.
What it does not touch, which matters for how it is used off label. The same document states that letrozole “has not been shown to significantly affect adrenal corticosteroid synthesis, aldosterone synthesis, or synthesis of thyroid hormones”. The selectivity is real. The consequence people forget is that the specificity cuts both ways: nothing else in the steroid pathway compensates when estrogen falls, so the entire effect lands on estrogen-dependent tissue — bone, lipids, joints, brain.
Cell, rodent, human — and where it stops
Start where the evidence is strongest, because it is not where this drug is bought. Franik 2022 is a Cochrane review of 41 randomized trials in 6522 women with anovulatory polycystic ovary syndrome. Against the SERM standard, letrozole produced higher live birth rates: OR 1.72, 95% CI 1.40 to 2.11, I² = 0%, 11 trials, 2060 participants, high-certainty evidence — the review's own translation is that a woman with a 20% chance on a SERM has a 27% to 35% chance on letrozole. Clinical pregnancy followed: OR 1.69 (1.45 to 1.98), 23 trials, 3321 participants. Ovarian hyperstimulation was 0.5% in both arms, miscarriage per pregnancy 25% versus 24%, multiple pregnancy 2.2% versus 1.6%. High-certainty evidence on every one of those. That is a stronger evidence base than most compounds on this site have for anything.
Then the oncology record, which is where the dose and the safety numbers come from. Femara label 2026 carries the adjuvant breast cancer indications and the BIG 1-98 dataset. Both are postmenopausal women with hormone-receptor-positive disease, taking 2.5 mg once daily for years. Every estrogen-suppression figure on this page was measured in that population.
And here is exactly where it stops for the reader this site has. There is no randomized trial of letrozole for estrogen control in men on testosterone. Not a small one — none. The entire off-label case rests on transferring an enzyme mechanism from postmenopausal women, whose remaining estrogen is made peripherally in adipose tissue from adrenal androgens, to men on exogenous testosterone, whose substrate supply is far higher and pharmacological rather than physiological. The enzyme is the same. The substrate concentration, the tissue distribution and the feedback loop are not, and that is the specific obstacle nobody states.
One consequence of that obstacle is checkable and rarely checked. In a man, suppressing estradiol removes the negative feedback estradiol exerts at the hypothalamus and pituitary, so luteinizing hormone and testosterone rise — which is why the same drug class gets used to raise testosterone in hypogonadal men and to lower estrogen in men already on it. Those are two different protocols pointing at the same enzyme, and a page that describes only one of them has told half the story.
Letrozole pharmacokinetics — how much of it actually gets in
What degrades it. Femara label 2026: letrozole is metabolized principally by CYP3A4 to a carbinol metabolite, with CYP2A6 forming that metabolite and its ketone analog. About 90% of a radiolabeled dose is recovered in urine, of which at least 75% is the glucuronide of the carbinol metabolite. So the exit is hepatic oxidation followed by glucuronidation and renal excretion of the conjugate — not renal clearance of parent drug.
The oral barrier, and there is none worth discussing. “Rapidly and completely absorbed from the gastrointestinal tract”, and absorption is not affected by food Femara label 2026. No injectable form exists and an injection would change nothing: this is a small, orally complete molecule, unlike every peptide on this site where the route is the whole problem.
The arithmetic that explains the crashes, and it is the most practical paragraph on this page. Terminal elimination half-life is about 2 days, and steady state after 2.5 mg daily is reached in 2 to 6 weeks Femara label 2026. Two consequences follow directly. First, the concentration on day 3 is not the concentration on day 30 — somebody who feels fine in week one is measuring an exposure roughly half of what they will eventually sit at. Second, the same arithmetic runs backwards: after stopping, five half-lives is about 10 days, so a dose correction made today does not show its full effect for a week and a half. Compare anastrozole, whose half-life is around 48 hours as well U.S. Food and Drug Administration 2011, and exemestane, which is dosed at ten times the milligram amount US Food and Drug Administration 2024 because it is a different kind of molecule doing a different kind of inhibition.
Why the CYP3A4 route is the interaction that matters. A drug cleared principally by CYP3A4 is exposed to every strong inducer and inhibitor of that enzyme, and this readership routinely takes at least one — modafinil induces CYP3A4, several azole antifungals and macrolides inhibit it. An induced patient is under-dosed and an inhibited one is over-dosed, at the same tablet, and the 2-to-6-week accumulation window means neither is obvious for a fortnight.
What would have to be true, and how you would know it was not
Four predictions. The first is the measurement that should decide whether this drug is used at all, and the third cuts against it.
1. Sensitive estradiol, drawn at the right time. Not the standard immunoassay — the LC-MS/MS sensitive assay, because immunoassays are unreliable at the low concentrations this drug produces, which is exactly why Bertelsen 2024 built an ultrasensitive method to do its comparison. Draw at baseline and again at 4 to 6 weeks, which is when steady state actually arrives Femara label 2026. A four-day recheck is measuring an incomplete accumulation and will read falsely reassuring.
2. The prediction from the head-to-head: this drug will over-suppress where exemestane would not. In the same patients, residual estrone was 0.2 against 1.8 pmol/L Bertelsen 2024. If somebody has crashed estradiol on letrozole, the mechanistic expectation is that the same person on the steroidal drug lands higher — and that swap has never been tested in anyone using these off label.
3. Against the product: joint pain will arrive, and it is the commonest reason people stop. Arthralgia and arthritis were reported in 25.4% of letrozole patients in the adjuvant trial Femara label 2026, and Hyder 2021 describes the aromatase-inhibitor-associated musculoskeletal syndrome — bone loss plus arthralgia — as affecting up to half of women on AI therapy and as a leading cause of treatment discontinuation. A compound bought to improve how somebody feels has a one-in-four to one-in-two chance of making their joints worse.
4. Bone and lipids, which are the two silent ones. In the adjuvant trial the median lumbar spine bone mineral density fell 4.1% at 24 months on letrozole against a 0.3% rise on tamoxifen; fractures ran 14.7% versus 11.4% and osteoporosis 5.1% versus 2.7% at a median 96 months. Hypercholesterolemia was reported in 52.3% of letrozole patients against 28.6% on tamoxifen Femara label 2026. So: a lipid panel at baseline and at 12 weeks, and a DEXA before any course measured in years rather than weeks. Neither is routine in this readership and both are predicted by the mechanism.
What nobody has tested yet
Nobody has run a dose-response study below 2.5 mg. The label knows one dose Femara label 2026, and the entire off-label practice around this drug consists of quartering and eighthing that tablet. There is no published estradiol-versus-dose curve at 0.3, 0.6 or 1.25 mg in anybody, so the most common real-world use of letrozole outside oncology is happening in a region of the dose axis that has never been characterized. This is an ordinary pharmacology study and the assay to do it already exists Bertelsen 2024.
Nobody has done the head-to-head in men. Bertelsen 2024 is the model: same person, both drugs, ultrasensitive assay. Run it in men on stable testosterone against anastrozole and the field would have, for the first time, a real basis for choosing between two drugs it has been choosing between on forum consensus for twenty years.
Nobody has established a lower bound for estradiol in men. The harm from over-suppression is real and mechanistically obvious — bone, lipids, libido, mood — and there is no trial-derived floor to aim above. Every number circulating for it is observational or invented. The study that would fix it is a dose-titration series with a sensitive assay and a bone endpoint, and it has never been attempted.
Extrapolation, labeled as such. If letrozole's advantage over exemestane really is potency rather than kind, three things should follow that nobody has looked for. The two should converge at sufficiently low letrozole doses, which the missing dose-response curve would show. The bone and lipid penalties should track residual estrogen rather than the drug — and Chen 2022 is a network meta-analysis comparing the steroidal inhibitor's bone safety against the nonsteroidal ones, which is the right question asked in the wrong population for this readership. And the joint syndrome Hyder 2021 should be dose-dependent rather than idiosyncratic, which is testable in a week with a symptom diary and has not been reported.
Letrozole — its own safety story, not its class's
Four things this drug owns, and the first is not negotiable.
It causes fetal harm and the label says so as a contraindication Femara label 2026. This is not a warning buried in a section — pregnancy is a listed contraindication, and letrozole is simultaneously a drug used to cause pregnancy Franik 2022. Those two facts sit together because ovulation induction is a supervised, cycle-timed use with pregnancy testing around it. Any other use in a woman who could become pregnant is a different situation entirely.
The bone signal is quantified and it is the one that compounds silently. Median lumbar spine bone mineral density fell 4.1% over 24 months against a 0.3% gain on the comparator; fracture incidence was 14.7% against 11.4% and osteoporosis 5.1% against 2.7% at a median of 96 months Femara label 2026. Nothing about that is felt until something breaks, which is why a DEXA belongs before a long course rather than after a fracture.
Cholesterol moved in more than half of the treated arm. Hypercholesterolemia in 52.3% on letrozole against 28.6% on tamoxifen, with grade 3-4 events at 0.4% versus 0.1% Femara label 2026. Estrogen is a lipid-regulating hormone and removing it does what removing it should do. A reader on this site is unusually likely to already be tracking a lipid panel, which makes this the cheapest of all the checks on the page.
And the honest framing of the whole card. Every number here comes from postmenopausal women with breast cancer taking 2.5 mg daily for years, or from women being treated for infertility. Letrozole is a prescription medicine, the Vault carries no buy route for it, and the reason the page exists at all is that Anastrozole U.S. Food and Drug Administration 2011 and Exemestane US Food and Drug Administration 2024 both had pages and the strongest drug of the three did not — which meant the one most likely to over-suppress was the one with no page to say so.
Sources read for this page
- U.S. Food and Drug Administration. FEMARA (letrozole) tablets - full prescribing information, including the 75% to 95% estrogen-suppression statement, the bone mineral density and hypercholesterolemia warnings and the BIG 1-98 adverse reaction table. DailyMed, U.S. National Library of Medicine; Novartis Pharmaceuticals label version 32, revised June 2026
- Bertelsen BE, Almas B, Fjermeros K, Viste K, Geisler SB, Sauer T, Selsas K, Geisler J. Superior suppression of serum estrogens during neoadjuvant breast cancer treatment with letrozole compared to exemestane. Breast Cancer Research and Treatment 2024 · PMID 38649619
- Franik S, Le QK, Kremer JA, Kiesel L, Farquhar C. Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary syndrome. Cochrane Database of Systematic Reviews 2022 · PMID 36165742
- Hyder T, Marino CC, Ahmad S, Nasrazadani A, Brufsky AM. Aromatase Inhibitor-Associated Musculoskeletal Syndrome: Understanding Mechanisms and Management. Frontiers in Endocrinology 2021 · PMID 34385978
- Chen S, Bo L, Lv D, Ma F. Bone Safety Profile of Steroidal Aromatase Inhibitor in Comparison to Nonsteroidal Aromatase Inhibitors in Postmenopausal Women with Breast Cancer: A Network Meta-Analysis. Breast Care (Basel) 2022 · PMID 36156912
- US Food and Drug Administration. AROMASIN (exemestane) tablets, for oral use - full prescribing information.. FDA approved labeling, revision 2024
- U.S. Food and Drug Administration. ARIMIDEX (anastrozole) tablets, for oral use - full prescribing information (NDA 020541).. FDA approved labeling, revision 2011
Letrozole — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- Two different mechanisms with one shared consequence: less estrogen signaling. Aromatase inhibitors (anastrozole, exemestane) stop testosterone converting to estradiol; SERMs (tamoxifen, raloxifene, clomiphene, enclomiphene) block or activate the receptor depending on the tissue.
- The predicted harm is the same either way and it is not the one people expect. Estrogen is not a side effect to be eliminated — it is required for bone density, joint comfort, lipid handling, libido and mood in men as well as women. Crushing it produces aching joints, flat libido, low mood and, over years, measurable bone loss.
- Clomiphene specifically is a mixture of two isomers and the longer-lived one (zuclomiphene) accumulates; the visual disturbances reported on it are attributed to that accumulation. Enclomiphene is the isolated isomer, which is the entire argument for it.
What has actually been reported
- Well documented in oncology use: hot flushes, joint pain and reduced bone mineral density on AIs; venous thromboembolism and endometrial changes on tamoxifen.
- Visual disturbance on clomiphene is uncommon but real and is a reason to stop rather than push through.
How to reduce the risk
Same mechanism as the prediction.
- The dose almost everyone gets wrong is the AI dose. These are used in oncology to drive estradiol as close to zero as possible; that is a cancer-treatment goal and it is the wrong target for anyone else. Most people feeling terrible on a protocol are over-suppressing estradiol.
- Measure before adjusting, and measure with the sensitive (LC-MS/MS) estradiol assay — the standard immunoassay is unreliable in men and produces numbers people then medicate.
- If an AI is genuinely needed, the lowest effective dose intermittently beats a fixed daily one. Bone density is worth tracking on anything run for more than a year.
What it does to your bloodwork
A fact about the assay.
- Sensitive estradiol, total and free testosterone, LH and FSH, a lipid panel, and — for long-term use — a DEXA for bone density.
Don't run this if
- You are only using one because of a number rather than a symptom. An estradiol reading with no symptoms attached is not a reason to medicate.
The honest unknown
- Long-term outcomes of AI use in otherwise healthy men, at the doses used outside oncology, have not been studied. The bone and lipid consequences are extrapolated from populations taking them for a different reason.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Letrozole — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What Letrozole moves on your bloodwork
Expected direction, not a measured one.
- Complete Blood Count (CBC) with Differential — ↑ expected to rise
Hematocrit and hemoglobin rise — androgens stimulate erythropoiesis. This is the most reliably predictable movement of any compound in the Vault.
What to do: This is the number that decides whether you keep going. Baseline and every 3 months. Dehydration on the draw day inflates it, so hydrate normally or you will chase a false reading. - Total Testosterone — ↑ expected to rise
Expected. Trough vs peak matters enormously — the same protocol reads completely differently depending on when you drew.
What to do: Draw at the same point in the cycle every time or the trend is noise. - LH & FSH — ↓ expected to fall
Suppressed by negative feedback. This is the mechanism, not a side effect — and it is why exogenous androgen shuts down your own production.
What to do: Relevant if fertility matters to you. Worth knowing before, not after. - Estradiol, Sensitive (LC/MS-MS) — ↑ expected to rise
Aromatization converts a fraction to estradiol, and it rises with the androgen. Use the sensitive (LC-MS/MS) assay — the standard immunoassay is unreliable in men and produces numbers people then medicate.
What to do: If you are reading estradiol in a man, the assay choice matters more than the result. - SHBG (Sex Hormone-Binding Globulin) — ↓ expected to fall
Falls with androgen exposure, which raises the free fraction — so free testosterone can climb faster than total.
What to do: Read total and SHBG together; total alone understates what changed. - Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) — ↓ expected to worsen
HDL falls, sometimes markedly. Oral 17-alpha-alkylated compounds do this far more aggressively than injectable esters.
What to do: Baseline and 12 weeks. ApoB is the better long-term read than LDL-C. - PSA (Total + Free + % Free) — ↑ expected to rise
Androgens can raise PSA modestly. It does not create prostate cancer that wasn't there, but it can unmask it.
What to do: Baseline before starting matters — without it, a later number has nothing to be compared against.
- Dose range and how to work up to it
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — Letrozole in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Letrozole
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| Total Testosterone | The baseline you can't reconstruct later |
| Free Testosterone | The fraction that does anything — total alone misleads |
| SHBG (Sex Hormone-Binding Globulin) | Explains a normal total sitting on top of a low free |
| Estradiol, Sensitive (LC/MS-MS) | The other half of the ratio, and the source of most symptoms |
| LH & FSH | Separates a testicular problem from a pituitary one |
The “Low T? Rule Out the Reversible Causes First” panel covers these in one order — 11 markers, $211.50 with the discount applied.
Check results you already have → · All 103 markers A–Z
Letrozole — frequently asked questions
What is Letrozole?
Letrozole (Femara — nonsteroidal aromatase inhibitor) is a hormonal & sexual research compound. A nonsteroidal competitive inhibitor of aromatase (CYP19A1), the enzyme that converts androstenedione to estrone and testosterone to estradiol. Reversible, unlike exemestane, which is a steroidal substrate analog that inactivates the enzyme permanently. The label reports suppression of plasma estradiol, estrone and estrone sulfate by 75-95% from baseline, with no significant effect on adrenal corticosteroid, aldosterone or thyroid hormone synthesis. Cleared by CYP3A4 and CYP2A6 to a carbinol metabolite, then glucuronidated and excreted renally.
Where can I find Letrozole dosing and protocols?
Dosing, the reconstitution calculator and Coach Cam's full Letrozole protocol are available to members inside Skool. This public page covers what Letrozole is, how it works and the evidence.
What is the half-life of Letrozole?
Letrozole has an approximate half-life of ~2 days (terminal); steady state takes 2-6 weeks, which is part of what determines how often it's dosed.
What's the evidence behind Letrozole?
Current evidence level: FDA-approved (adjuvant and advanced breast cancer, postmenopausal women). High-certainty Cochrane evidence for ovulation induction in PCOS. No trial in men.. Letrozole is offered for research purposes only and is not an approved medicine.
What Letrozole is used for
Letrozole appears under 1 goal in the goal router.
Related Hormonal & Sexual compounds
Where this goes next
The pages here are the frameworks. The protocols — the dosing, the order to correct things in, the week-by-week schedule and what to retest — are inside Skool.